NATERA, INC. (NTRA) — Fundamental Analysis

Natera is a genetic testing company on a compelling growth trajectory — revenue has compounded at roughly 41% annually over the past three and five years, vaulting from $820 million in 2022 to $2.3 billion in 2025. The story is not yet one of profitability: Natera has posted operating losses every single year in its filing history, though those losses are shrinking meaningfully as a percentage of revenue. The most recent quarter (ending June 2026) shows the clearest sign yet of approaching the break-even horizon, with an operating margin of about -10% and a gross margin finally reported at approximately 5%. The balance sheet remains solid with current assets comfortably exceeding short-term obligations, and debt is low. In plain terms: Natera is a high-growth, still-unprofitable business that is rapidly scaling its way toward sustainable economics — investors are essentially betting on continued volume growth closing the remaining profitability gap.

Snapshot & Big Picture

Natera develops and commercializes genetic tests, most notably in prenatal health (its Panorama NIPT test), oncology (Signatera), and organ health. The company has grown revenue from $190 million in 2015 to $2.3 billion in fiscal year 2025 — a tenfold increase over a decade. Despite that dramatic top-line expansion, the company has never turned an annual profit, relying on equity and debt markets to fund operations. That said, the trend is clearly moving in the right direction: operating losses as a share of revenue have compressed dramatically, from -75% in 2021 to -13% in 2025, as scale improves unit economics.

Latest Quarter Snapshot

The quarter ending June 30, 2026 is the most current financial data available and reflects conditions more recent than the full-year 2025 figures. Natera posted quarterly revenue of $752.8 million, an annualized run rate of approximately $3 billion. The operating margin was -10.1% and the net margin -8.9%, both continuing the multi-year improvement trend. Notably, a gross margin of 5.2% is reported for this quarter — prior annual filings did not report gross margin in the data available, making this the clearest direct read on unit-level economics. While a 5% gross margin remains thin, it suggests the company is at or near the point where additional volume will flow more directly to the bottom line. The current ratio stood at approximately 3.0, indicating solid short-term liquidity. Debt-to-equity ticked up slightly to 0.20 compared to the 0.047 reported at year-end 2025, though it remains at a manageable level. Capital expenditures for the quarter were $22.1 million, representing about 2.9% of revenue.

Profitability

Natera has never reported an annual profit, but the direction of travel is unmistakable. The worst years for operating margin were 2021 and 2022, when rapid expansion in headcount, lab infrastructure, and sales outpaced revenue recognition. Since then, as volume has surged — particularly in the Signatera oncology franchise — the margin profile has improved sharply. The operating margin improved from -41% in 2023 to -13% in 2025, a 28-percentage-point swing in just two years. Net margin followed a similar path: from -40% in 2023 to -9% in 2025. EBITDA losses, while still large in absolute dollar terms, have also narrowed as a percentage of the growing revenue base. The trajectory, if maintained, points to potential operating breakeven within the next few years — though that outcome remains dependent on continued volume growth and reimbursement stability.

Financial Health

Natera's balance sheet is in good shape relative to its stage of development. The current ratio has consistently remained well above 1.0 across the entire filing history, ranging from a low of about 1.7 in 2017 to nearly 5.0 in 2021, and sitting at approximately 3.0 in the most recent quarter. This means current assets are roughly three times current liabilities — a comfortable liquidity buffer for a company still burning cash.

Debt levels have also declined dramatically. Debt-to-equity was above 1.5 in 2017–2018, reflecting early heavy borrowing, but fell to just 0.047 by fiscal year-end 2025 as equity financing diluted the relative debt load. The slight uptick to 0.20 in the June 2026 quarter is worth monitoring but is not alarming at this level.

Capital Expenditures: Natera's capex profile reflects a business building laboratory and processing infrastructure. Annual capex has grown in dollar terms — from $4.97 million in 2019 to $106.2 million in 2025 — as the company invested in expanded testing capacity. However, as a percentage of revenue, capex intensity has remained relatively contained and actually trended downward in recent years:

The capex-to-revenue ratio has broadly declined from peak levels, suggesting the company is becoming somewhat more capital-efficient as existing infrastructure supports higher throughput. Absolute capex is rising, but at a slower rate than revenue — a healthy dynamic implying improving operating leverage on the infrastructure side.

Growth

Natera's revenue growth rates across all three measurement windows are exceptional for a company of its size:

All three windows are available given Natera's SEC filing history stretching back to at least 2015. A 3-year CAGR of 41.1% and a 5-year CAGR of 42.6% rank Natera among the fastest-growing large-cap diagnostics companies in the market. Even the 10-year CAGR of 28.3% — which captures slower early years — is well above typical healthcare sector averages. The acceleration in the 3- and 5-year windows relative to the 10-year figure reflects the inflection point Natera hit as its oncology and organ health franchises gained meaningful clinical adoption and reimbursement coverage alongside the core prenatal business.

Source Filings

• 10-Q filed August 7, 2026 — Period ending June 30, 2026
• 10-Q filed May 8, 2026 — Period ending March 31, 2026